The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non–Small-Cell Lung Cancer
Open accessAbstract
Purpose: The ROS1 tyrosine kinase is activated through ROS1 gene rearrangements in 1% to 2% of non–small-cell lung cancers (NSCLCs), which confer sensitivity to treatment with the anaplastic lymphoma kinase (ALK)/ROS1/mesenchymal-epithelial transition factor inhibitor crizotinib. Currently, insights into patterns of metastatic spread and mechanisms of crizotinib resistance among patients with ROS1-positive disease are limited. Patients and Methods: We reviewed clinical and radiographic imaging data of patients with ROS1- and ALK-positive NSCLC to compare patterns of metastatic spread at initial metastatic diagnosis. To determine molecular mechanisms of crizotinib resistance, we analyzed repeat biopsy specimens from a cohort of patients with ROS1-positive disease who progressed on crizotinib. Results: We identified 39 and 196 patients with advanced ROS1- and ALK-positive NSCLC, respectively. Patients with ROS1-positive disease had significantly lower rates of extrathoracic metastases ( ROS1, 59.0%; ALK, 83.2%; P = .002), including lower rates of brain metastases ( ROS1, 19.4%; ALK, 39.1%; P = .033), at initial metastatic diagnosis. Despite similar overall survival between patients with ALK- and ROS1-positive NSCLC treated with crizotinib (median, 3.0 v 2.5 years, respectively; P = .786), patients with ROS1-positive NSCLC also had a significantly lower cumulative incidence of brain metastases (34% v 73% at 5 years; P < .001). In addition, we identified 16 patients who underwent a total of 17 repeat biopsies after progression on crizotinib. ROS1 resistance mutations were identified in 53% of specimens, including nine (64%) of 14 non–brain metastasis specimens. ROS1 mutations included G2032R (41%), D2033N (6%), and S1986F (6%). Conclusion: Compared with ALK rearrangements, ROS1 rearrangements are associated with lower rates of extrathoracic metastases, including fewer brain metastases, at initial metastatic diagnosis. ROS1 resistance mutations, particularly G2032R, appear to be the predominant mechanism of resistance to crizotinib, which underscores the need to develop novel ROS1 inhibitors with activity against these resistant mutants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Self-citationGoldstraw, P., Crowley, J., Chansky, K., Giroux, D. J., Groome, P. A., Rami-Porta, R., Postmus, P. E., Rusch, V., & Sobin, L. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31812f3c1a · Cited by 3,655
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Self-citationFirst-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
Self-citationClinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
Shaw, A. T., Yeap, B. Y., Mino-Kenudson, M., Digumarthy, S. R., Costa, D. B., Heist, R. S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6993 · Cited by 1,870
Self-citationROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Bergethon, K., Shaw, A. T., Ignatius Ou, S.-H., Katayama, R., Lovly, C. M., McDonald, N. T., Massion, P. P., Siwak-Tapp, C., Gonzalez, A., Fang, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6345 · Cited by 1,555
Self-citationRET, ROS1 and ALK fusions in lung cancer
Takeuchi, K., Soda, M., Togashi, Y., Suzuki, R., Sakata, S., Hatano, S., Asaka, R., Hamanaka, W., Ninomiya, H., Uehara, H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2658 · Cited by 1,320
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Katayama, R., Shaw, A. T., Khan, T. M., Mino-Kenudson, M., Solomon, B. J., Halmos, B., Jessop, N. A., Wain, J. C., Yeo, A. T., Benes, C., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003316 · Cited by 1,309
Self-citationSoria, J.-C., Tan, D. S. W., Chiari, R., Wu, Y.-L., Paz-Ares, L., Wolf, J., Geater, S. L., Orlov, S., Cortinovis, D., Yu, C.-J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30123-x · Cited by 1,151
Gainor, J. F., Dardaei, L., Yoda, S., Friboulet, L., Leshchiner, I., Katayama, R., Dagogo-Jack, I., Gadgeel, S., Schultz, K., Singh, M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0596 · Cited by 1,148
Self-citationBrastianos, P. K., Carter, S. L., Santagata, S., Cahill, D. P., Taylor-Weiner, A., Jones, R. T., Van Allen, E. M., Lawrence, M. S., Horowitz, P. M., Cibulskis, K., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0369 · Cited by 1,082
Doebele, R. C., Pilling, A. B., Aisner, D. L., Kutateladze, T. G., Le, A. T., Weickhardt, A. J., Kondo, K. L., Linderman, D. J., Heasley, L. E., Franklin, W. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2906 · Cited by 1,063
Hata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4040 · Cited by 985
Self-citationAnchored multiplex PCR for targeted next-generation sequencing
Zheng, Z., Liebers, M., Zhelyazkova, B., Cao, Y., Panditi, D., Lynch, K. D., Chen, J., Robinson, H. E., Shim, H. S., Chmielecki, J., et al. (2014) · Nature Medicine · doi:10.1038/nm.3729 · Cited by 915
Self-citationDrilon, A., Siena, S., Ou, S.-H. I., Patel, M., Ahn, M. J., Lee, J., Bauer, T. M., Farago, A. F., Wheler, J. J., Liu, S. V., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1237 · Cited by 826
Self-citationGenetic determinants of cancer metastasis
Nguyen, D. X., & Massagué, J. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2101 · Cited by 801
CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
Costa, D. B., Kobayashi, S., Pandya, S. S., Yeo, W.-L., Shen, Z., Tan, W., & Wilner, K. D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1313 · Cited by 596
Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1
Awad, M. M., Katayama, R., McTigue, M., Liu, W., Deng, Y.-L., Brooun, A., Friboulet, L., Huang, D., Falk, M. D., Timofeevski, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215530 · Cited by 416
Self-citationStereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy
Huber, K. V. M., Salah, E., Radic, B., Gridling, M., Elkins, J. M., Stukalov, A., Jemth, A.-S., Göktürk, C., Sanjiv, K., Strömberg, K., et al. (2014) · Nature · doi:10.1038/nature13194 · Cited by 395
Molecular Pathways: ROS1 Fusion Proteins in Cancer
Davies, K. D., & Doebele, R. C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2851 · Cited by 373
Mazières, J., Zalcman, G., Crinò, L., Biondani, P., Barlesi, F., Filleron, T., Dingemans, A.-M. C., Léna, H., Monnet, I., Rothschild, S. I., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3302 · Cited by 369
Crinò, L., Ahn, M.-J., De Marinis, F., Groen, H. J. M., Wakelee, H., Hida, T., Mok, T., Spigel, D., Felip, E., Nishio, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.5936 · Cited by 350
Self-citationNovel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions
Gainor, J. F., & Shaw, A. T. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0095 · Cited by 342
Self-citationWu, Y.-L., Yang, J. C.-H., Kim, D.-W., Lu, S., Zhou, J., Seto, T., Yang, J.-J., Yamamoto, N., Ahn, M.-J., Takahashi, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.5587 · Cited by 326
Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer
Doebele, R. C., Lu, X., Sumey, C., Maxson, D. A., Weickhardt, A. J., Oton, A. B., Bunn, P. A., Barón, A. E., Franklin, W. A., Aisner, D. L., et al. (2012) · Cancer · doi:10.1002/cncr.27409 · Cited by 280
Zou, H. Y., Li, Q., Engstrom, L. D., West, M., Appleman, V., Wong, K. A., McTigue, M., Deng, Y.-L., Liu, W., Brooun, A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420785112 · Cited by 267
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer
Hrustanovic, G., Olivas, V., Pazarentzos, E., Tulpule, A., Asthana, S., Blakely, C. M., Okimoto, R. A., Lin, L., Neel, D. S., Sabnis, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3930 · Cited by 267
Yoshida, T., Oya, Y., Tanaka, K., Shimizu, J., Horio, Y., Kuroda, H., Sakao, Y., Hida, T., & Yatabe, Y. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.8732 · Cited by 266
Resistance Mechanisms to Targeted Therapies in ROS1 + and ALK + Non–small Cell Lung Cancer
McCoach, C. E., Le, A. T., Gowan, K., Jones, K., Schubert, L., Doak, A., Estrada-Bernal, A., Davies, K. D., Merrick, D. T., Bunn, P. A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2452 · Cited by 247
Woo, C. G., Seo, S., Kim, S. W., Jang, S. J., Park, K. S., Song, J. Y., Lee, B., Richards, M. W., Bayliss, R., Lee, D. H., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw693 · Cited by 219
Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer
Katayama, R., Kobayashi, Y., Friboulet, L., Lockerman, E. L., Koike, S., Shaw, A. T., Engelman, J. A., & Fujita, N. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1385 · Cited by 201
Self-citationGadgeel, S. M., Shaw, A. T., Govindan, R., Gandhi, L., Socinski, M. A., Camidge, D. R., De Petris, L., Kim, D.-W., Chiappori, A., Moro-Sibilot, D. L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.4639 · Cited by 191
Self-citationDrilon, A., Somwar, R., Wagner, J. P., Vellore, N. A., Eide, C. A., Zabriskie, M. S., Arcila, M. E., Hechtman, J. F., Wang, L., Smith, R. S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2013 · Cited by 166
Facchinetti, F., Loriot, Y., Kuo, M.-S., Mahjoubi, L., Lacroix, L., Planchard, D., Besse, B., Farace, F., Auger, N., Remón, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0917 · Cited by 156
Self-citationThe Central Nervous System as a Sanctuary Site in ALK-Positive Non–Small-Cell Lung Cancer
Gainor, J. F., Ou, S. I., Logan, J. K., Borges, L. F., & Shaw, A. T. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000029 · Cited by 137
Self-citationSong, A., Kim, T. M., Kim, D., Kim, S., Keam, B., Lee, S., & Heo, D. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1350 · Cited by 136
Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer
Davies, K. D., Mahale, S., Astling, D. P., Aisner, D. L., Le, A. T., Hinz, T. K., Vaishnavi, A., Bunn, P. A., Heasley, L. E., Tan, A. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082236 · Cited by 128
Clinical Activity of Alectinib in Advanced RET -Rearranged Non–Small Cell Lung Cancer
Lin, J. J., Kennedy, E., Sequist, L. V. D., Brastianos, P. K., Goodwin, K. E., Stevens, S. E., Wanat, A. C., Stober, L. L., Digumarthy, S. R., Engelman, J. A., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.08.126 · Cited by 104
Self-citationAn Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer
Dziadziuszko, R., Le, A. T., Wrona, A., Jassem, J., Camidge, D. R., Varella‐Garcia, M., Aisner, D. L., & Doebele, R. C. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.04.001 · Cited by 83
Chong, C. R., Bahcall, M., Capelletti, M., Kosaka, T., Ercan, D., Sim, T., Sholl, L. M., Nishino, M., Johnson, B. E., Gray, N. S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1601 · Cited by 83
Activation of RAS family members confers resistance to ROS1 targeting drugs
Cargnelutti, M., Corso, S., Pergolizzi, M., Mévellec, L., Aisner, D. L., Dziadziuszko, R., Varella‐Garcia, M., Comoglio, P. M., Doebele, R. C., Vialard, J. E., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.3311 · Cited by 80
EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases
Vaishnavi, A., Schubert, L., Rix, U., Marek, L. A., Le, A. T., Keysar, S. B., Glogowska, M. J., Smith, M. A., Kako, S. L., Sumi, N. J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0109 · Cited by 76
Zhang, L., Jiang, T., Zhao, C., Li, W., Li, X., Zhao, S., Liu, X., Jia, Y., Yang, H., Ren, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12612 · Cited by 55
He, Y., Zhang, X., Yang, J., Niu, F., Zeng, Z., Yan, H., Xu, C., Guan, J.-L., Zhong, W., Yang, L., et al. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.06.006 · Cited by 37
Juan, Ó., & Popat, S. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.11.007 · Cited by 7
Cited by
Thai, A. A., Solomon, B. J., Sequist, L. V., Gainor, J. F., & Heist, R. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00312-3 · Cited by 2,576
Self-citationTrends in kinase drug discovery: targets, indications and inhibitor design
Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00252-y · Cited by 779
Shaw, A. T., Felip, E., Bauer, T. M., Besse, B., Navarro, A., Postel-Vinay, S., Gainor, J. F., Johnson, M., Dietrich, J., James, L. P., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30680-0 · Cited by 659
Self-citationDrilon, A., Siena, S., Dziadziuszko, R., Barlesi, F., Krebs, M. G., Shaw, A. T., de Braud, F., Rolfo, C., Ahn, M.-J., Wolf, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30690-4 · Cited by 528
Self-citationThird-generation EGFR and ALK inhibitors: mechanisms of resistance and management
Cooper, A. J., Sequist, L. V., & Lin, J. J. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00639-9 · Cited by 508
Self-citation
Metadata
- Authors
- Gainor, J. F., Tseng, D., Yoda, S., Dagogo-Jack, I., Friboulet, L., Lin, J. J., Hubbeling, H. G., Dardaei, L., Farago, A. F., Schultz, K. R., Ferris, L. A., Piotrowska, Z., Hardwick, J., Huang, D., Mino-Kenudson, M., Iafrate, A. J., Hata, A. N., Yeap, B. Y., & Shaw, A. T.
- Venue
- JCO Precision Oncology
- Published
- 2017-11
- Volume
- 2017
- Issue
- 1
- Pages
- 1-13
- ISSN
- 2473-4284 (ISSN-L)
- OpenAlex
- W2745391639
- Cited by
- 264
- References
- 49
- FWCI
- 22.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.